Catatonia and its treatment

Schizophrenia Bulletin

Volumn 36, Issue 2, 2010, Pages 239-242

  Rosebush, Patricia I ^a   Mazurek, Michael F ^a,b  

^a ST JOSEPH S HOSPITAL   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Benzodiazepines; Catatonia; Treatment

Indexed keywords

BENZODIAZEPINE DERIVATIVE; LORAZEPAM; NEUROLEPTIC AGENT;

CATATONIA; DISEASE CLASSIFICATION; HUMAN; MOOD DISORDER; NEUROLEPTIC MALIGNANT SYNDROME; NOTE; PRIORITY JOURNAL; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CATATONIA; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; ELECTROCONVULSIVE THERAPY; HUMANS; NEUROLEPTIC MALIGNANT SYNDROME; SCHIZOPHRENIA, CATATONIC; SYNDROME;

EID: 77749264405     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbp141     Document Type: Note

References (27)

1. Walter-Ryan WG. Treatment for catatonic symptoms with muscular lorazepam. J Clin Psychopharmacol. 1985;5: 123-124.
2. Rosebush PI, Hildebrand AM, Furlong BG, Mazurek MF. Catatonic syndrome in a general psychiatric in-patient population: frequency, clinical presentation and response to loraze-pam. J Clin Psychiatry. 1990;51:357-362.
3. Yassa R, Iskandar H, Lalinec M, Cleto L. Lorazepam as an adjunct in the treatment of catatonic states: an open clinical trial of catatonic states. J Clin Psychopharmacol. 1990; 10:66-68.
4. Ungvari GS, Chiu HF, Chow LY, Lau BS, Tang WK. Ben-zodiazepines in the treatment of catatonic syndrome. Acta Psychiatr Scand. 1994;89:285-288.
5. Rosebush PI, Mazurek MF. Catatonia: re-awakening to a forgotten disorder. Mov Disord. 1999;14:395-397.
6. Fink M, Shorter E, Taylor M. Catatonia is not schizophrenia: Kraepelin's error and the need to recognize catatonia as an independent syndrome in medical nomenclature. Schizophr Bull. 2009; doi:10. 1093/schbul/sbp059.
7. Bush G, Fink M, Petrides G, Dowling F, Francis A. Catato-nia 1. Rating scale and standardized examination. Acta Psychiatr Scand. 1996;93:129-136.
8. Lee JW, Schwartz DL, Hallmayer J. Catatonia in a psychiatric intensive care facility: incidence and response to benzodiaze-pines. Ann Clin Psychiatry. 2000;12:89-96.
9. Kahlbaum KL, Lei Y, Pridon T, eds. Catatonia. Baltimore, MD: John Hopkins University Press 1973.
10. Rosebush PI, Mazurek MF. Catatonia: clinical features, differential diagnosis and treatment. In: Jeste DV, Friedman JH, eds. Current Clinical Neurology: Psychiatry for Neurologists. Totowa, NJ: Humana Press Inc; 2006:81-92.
11. Rosebush PI, Mazurek MF. Catatonia after benzodiazepine withdrawal. J Clin Psychopharmacol. 1996;16:315-319.
12. Ungvari GS, Chiu HF, Chow LY, Lau BS, Tang WK. Lor-azepam for chronic catatonia: a randomized, double-blind, placebo-controlled cross-over study. Psychopharmacology. 1999;142:393-398.
13. Gaind GS, Rosebush PI, Mazurek MF. Lorazepam treatment of acute and chronic catatonia in two mentally retarded brothers. J Clin Psychiatry. 1994;55:20-23.
14. Rosebush PI, MacQueen GM, Mazurek MF. Late-onset Tay-Sachs disease presenting as catatonic schizophrenia: diagnostic and treatment issues. J Clin Psychiatry. 1995;56:347-353.
15. Ungvari GS, Caroff SN, Gerevich J. The catatonia conundrum: evidence of psychomotor phenomena as a symptom dimension in psychotic disorders. Schizophr Bull. 2009; doi:10. 1093/schbul/sbp105.
16. Henry GW. Catatonia in animals. Am J Psychiatry. 1932;11:757-793.
17. Moskowitz AK. "Scared stiff ": catatonia as an evolutionary-based fear response. Psychol Rev. 2004;11:984-1002.
18. Weinberger DR, Kelly MJ. Catatonia and malignant syndrome: a possible complication of neuroleptic administration. Report of a case involving haloperidol. J Nerv Ment Dis. 1977;165:263-268.
19. White DAC, Robbins AH. Catatonia: harbinger of the neuro-lpetic malignant syndrome. Br J Psychiatry. 1991;1:419-421.
20. Lee JWY. Serum iron in catatonia and neuroleptic malignant syndrome. Biol Psychiatry. 1998;44:499-507.
21. Paparrigopoulos T, Tzavellas E, Ferentinos P, Mourikis I, Liappas J. Catatonia as a risk factor for the development of neuroleptic malignant syndrome. World J Biol Psychiatry. 2009;10:70-73.
22. Rosebush PI, Mazurek MF. Pharmacotherapy. In: Caroff SN, Mann SC, Francis A, Fricchione GL, eds. Catatonia: From Psychopathology to Neurobiology. Washington, DC: American Psychiatric Publishing Inc; 2004:141-150.
23. Rosebush PI, Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry. 1989;146:717-725. (Pubitemid 19149581)
24. Adityanjee, Aderibigbe YA, Mathews T. Epidemiology of neuroleptic malignant syndrome. Clin Neuropharmacol. 1999;22:151-158.
25. Rosebush PI, Mazurek MF. Serum iron and neuroleptic malignant syndrome. Lancet. 1991;338:149-151.
26. Rosebush PI, Anglin RE, Richards CR, Mazurek MF. Neu-roleptic malignant syndrome and the acute phase response. J Clin Psychopharmacol. 2008;28:459-461.
27. Mann SC, Caroff SN, Fricchione GL, Campbell EC, Greenstein RA. Malignant catatonia. In: Caroff SN, Mann SC, Francis A, Fricchione GL, eds. Catatonia: From Psycho-pathology to Neurobiology. Washington, DC: American Psychiatric Publishing Inc; 2004:105-120.